In the News
GLP-1s didn't increase risk of postop respiratory complications, study finds
Patients taking glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes before emergency surgery had a 3.5% incidence of postoperative respiratory complications compared with 4% among patients taking other diabetes medications.
Hyper-, hypokalemia with SGLT-2 inhibitors related to eGFR decrease after initiation
A decline of more than 30% in estimated glomerular filtration rate (eGFR) after initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy was associated with higher risk for hyperkalemia and hypokalemia in an observational study from Taiwan.
Evening workouts associated with lower mortality in type 2 diabetes
Patients with type 2 diabetes and obesity who worked out in the evening had greater reductions in risk for mortality and cardiovascular and microvascular disease than those who exercised in the morning or afternoon, a retrospective study found.
MKSAP Quiz: Diagnosing diabetes
This month's quiz asks readers to evaluate an asymptomatic 37-year-old man whose hemoglobin A1c level is 6.3% and fasting plasma glucose level is 135 mg/dL.
ACP releases guideline, systematic reviews on newer type 2 diabetes medications
The College recommended adding a sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist to metformin and lifestyle modifications after reviewing the effectiveness and cost-effectiveness of available medications.
SGLT-2 inhibitors associated with improved outcomes in stage 5 CKD patients
Patients with type 2 diabetes and stage 5 chronic kidney disease (CKD) had lower risk of progressing to dialysis or having a cardiovascular event if they took sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a study found.
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary
A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
Differentiating type 1 from type 2 diabetes in adults
Type 1 diabetes appears in adulthood more often than previously thought and its overt symptoms tend to be milder than those in children, making diagnosis tricky.
The latest on inpatient glucose control
A diabetes expert explained where glycemic targets for hospital patients should be now and what may be coming next, including continuous glucose monitors.